NEPHROGENIC DIABETES INSIPIDUS

✓ Medically ReviewedDISEASEID: MDBT0225🚨 TRIAGE: URGENTICD-10: N25.1

📖

Definition

CLINICAL DEFINITION

A disorder of water metabolism characterised by the inability of the renal collecting ducts to concentrate urine in response to arginine vasopressin (AVP), resulting in the excretion of large volumes of hypotonic urine.

IN PLAIN ENGLISH

A condition where the kidneys do not respond to the hormone that tells them to hold onto water, causing the body to produce large amounts of very dilute urine and leading to extreme thirst.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Nephrogenic Diabetes Insipidus is NOT central diabetes insipidus (which is caused by a lack of vasopressin production in the brain) and is NOT diabetes mellitus (which involves high blood sugar and insulin issues).

🔤

Word Breakdown

nephro-, diabetes, insipidus

=nephro- (Greek 'nephros' - kidney); diabetes (Greek 'diabainein' - to pass through); insipidus (Latin 'insipidus' - without taste, distinguishing it from diabetes mellitus which has sweet urine).

Literal Meaning: A condition of the kidneys characterised by the passing of tasteless (dilute) urine.

🏷️

Abbreviations

NDI=Nephrogenic Diabetes Insipidus — standard clinical abbreviation

🔄

Synonyms & Variants

Vasopressin-resistant diabetes insipidus›Renal diabetes insipidus›

🎯

Category-Specific Context

As a disease, nephrogenic diabetes insipidus represents a specific defect in renal tubular water reabsorption. It is classified based on aetiology into congenital (genetic mutations in AVPR2 or AQP2) and acquired forms (often drug-induced or secondary to electrolyte disturbances).

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Nephrology ClinicEndocrinology WardPaediatric Outpatient DepartmentEmergency DepartmentGeneral Medicine Ward

USAGE & DOCUMENTATION NOTES

Often abbreviated as NDI in clinical notes. Documented as 'polyuria and polydipsia secondary to NDI'. Urine output is typically recorded in strict fluid balance charts, often exceeding 3-4 litres per day in adults. Distinguishing between central and nephrogenic DI is a frequent clinical query requiring formal water deprivation testing.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Normal water homeostasis relies on arginine vasopressin (AVP) binding to V2 receptors on the basolateral membrane of the principal cells in the renal collecting duct. This activates adenylate cyclase, increasing intracellular cAMP, which triggers the insertion of aquaporin-2 (AQP2) water channels into the apical membrane, allowing water reabsorption. In nephrogenic diabetes insipidus, genetic mutations (e.g., AVPR2 or AQP2 genes) or acquired factors (e.g., lithium toxicity, hypercalcaemia, hypokalaemia) disrupt this signalling cascade or channel trafficking. Consequently, the collecting duct remains impermeable to water despite high circulating levels of AVP, resulting in the excretion of large volumes of hypotonic urine and a subsequent rise in plasma osmolality that drives intense thirst.

PRIMARY CAUSES

Congenital AVPR2 mutation

X-linked recessive mutation causing defective V2 receptor function, accounting for 90% of congenital cases.

Congenital AQP2 mutation

Autosomal recessive or dominant mutations causing defective aquaporin-2 water channel trafficking or function.

Hypercalcaemia

Elevated serum calcium impairs the renal concentrating ability by downregulating AQP2 and disrupting the medullary osmotic gradient.

Severe hypokalaemia

Chronic potassium depletion downregulates AQP2 expression and impairs the generation of the medullary concentration gradient.

Renal tubular acidosis or sickle cell trait

Medullary damage or washout impairs the countercurrent multiplier system, reducing the osmotic gradient necessary for water reabsorption.

💊

Drug-Induced Causes

💊 Lithium ↗

Mechanism: Enters principal cells via ENaC, inhibits glycogen synthase kinase-3 and adenylate cyclase, reducing cAMP and AQP2 transcription.

→ Discontinue lithium if possible; if essential, use amiloride to block lithium entry via ENaC, and ensure adequate hydration.

💊 Demeclocycline ↗

Mechanism: Interferes with the intracellular cAMP cascade post-AVP binding, intentionally inducing NDI in SIADH.

→ Usually reversible upon cessation; monitor fluid status and serum sodium.

💊 Cidofovir and Foscarnet ↗

Mechanism: Antiviral agents that can cause direct tubular toxicity and impair concentrating ability.

→ Ensure aggressive pre- and post-infusion hydration; monitor renal function closely.

💊 Amphotericin B ↗

Mechanism: Causes tubular damage and alters membrane permeability, leading to a concentrating defect.

→ Use lipid formulations if possible; maintain euvolaemia and correct electrolyte disturbances.

🌍

Epidemiology

Prevalence:Congenital NDI is rare, estimated at 1 to 9 per 1,000,000 live births. Acquired NDI is much more common, with up to 20-40% of patients on long-term lithium therapy developing some degree of urinary concentrating defect.

Age Group:Congenital forms present in infancy or early childhood with failure to thrive and hypernatraemic dehydration. Acquired forms typically present in adults, correlating with the onset of chronic lithium use, electrolyte disorders, or renal disease.

Sex Predilection:Male

Geographic Distribution:Globally distributed. No specific geographic concentration, though consanguinity may increase the prevalence of autosomal recessive AQP2 mutations in certain populations.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Infant with unexplained fever, irritability, and hypernatraemia — consider congenital NDI, as infants cannot articulate thirst and are at high risk of fatal hypernatraemic dehydration.
Patient on long-term lithium presenting with new-onset polyuria — evaluate for acquired NDI before irreversible renal tubular damage occurs; consider switching mood stabilisers or adding amiloride.

URGENT EVALUATION TRIGGERS

Serum sodium > 150 mmol/L with altered mental status or inability to access free water.
Signs of severe dehydration (tachycardia, hypotension, poor skin turgor) in an infant or child with polyuria.
Acute kidney injury superimposed on chronic polyuria.

Contraindications & Precautions

CONTRAINDICATIONS

Fluid restriction — absolutely contraindicated
as it rapidly leads to severe hypernatraemia and cardiovascular collapse.
Desmopressin (DDAVP) monotherapy — ineffective for nephrogenic DI and may cause fluid overload or hyponatraemia if the patient has partial central DI misdiagnosed as NDI.

SPECIAL PRECAUTIONS

Monitor serum sodium closely during acute illness or surgery when oral fluid intake is restricted.
Provide strict fluid balance charts and ensure unrestricted access to water and toilet facilities.
Caution with nephrotoxic drugs or NSAIDs
which can further impair renal function or interact with thiazide diuretics.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Hypernatraemic dehydration — inability to compensate for obligate water losses
particularly dangerous in infants who cannot access free water.
Hydronephrosis and megacystis — chronic high urine flow rates cause mechanical dilation of the urinary tract.
Renal impairment — recurrent dehydration and chronic tubular damage (especially with lithium) can lead to chronic kidney disease.
Developmental delay — secondary to recurrent hypernatraemic dehydration episodes in early childhood.

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Central Diabetes Insipidus

Shares the 'diabetes insipidus' name and polyuria/polydipsia presentation, but is caused by a lack of AVP secretion from the posterior pituitary, not renal resistance.

Diabetes Mellitus

Shares the 'diabetes' name and polyuria, but is driven by osmotic diuresis from hyperglycaemia, not a water channel defect.

Primary Polydipsia

Presents with polyuria and polydipsia, but is driven by excessive fluid intake suppressing AVP, rather than a renal defect.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Central Diabetes Insipidus

Key Distinguishing Feature: Urine osmolality increases significantly (>50%) after exogenous desmopressin administration during a water deprivation test.

Primary Polydipsia

Key Distinguishing Feature: Baseline serum sodium is often low-normal; urine osmolality increases gradually with water deprivation without needing desmopressin.

Osmotic Diuresis

Key Distinguishing Feature: Urine osmolality is higher (>300 mOsm/kg) due to the presence of osmotically active solutes like glucose or urea.

💎

Clinical Pearls

💎

Thiazide diuretics paradoxically reduce polyuria in NDI by inducing mild volume depletion, which enhances proximal tubular reabsorption of sodium and water, thereby decreasing distal delivery of filtrate to the collecting duct.

💎

Amiloride is particularly useful in lithium-induced NDI because it blocks the epithelial sodium channel (ENaC) in the collecting duct, preventing lithium entry into the principal cells and halting further tubular toxicity.

💎

A low-solute (low sodium and low protein) diet reduces the obligate renal solute load, thereby decreasing the volume of water required to excrete waste products and reducing overall urine output.

💎

Never restrict fluids in a patient with NDI. If a patient requires surgery or is nil by mouth, intravenous fluids matching their massive obligate free water losses must be meticulously calculated and administered.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"The patient, a 34-year-old male with bipolar disorder on long-term lithium therapy, presented with polyuria of 6 litres per day and a serum sodium of 148 mmol/L, consistent with acquired nephrogenic diabetes insipidus."

IN A SOAP NOTE

S: Patient reports excessive thirst and urinating every 1-2 hours, including waking 4 times at night to drink and void. O: Vitals: BP 110/70, HR 92. Mucous membranes slightly dry. Labs: Na 149 mmol/L, K 4.1, Ca 2.4, Serum Osm 305 mOsm/kg, Urine Osm 120 mOsm/kg. Post-DDAVP Urine Osm 125 mOsm/kg. A: Acquired nephrogenic diabetes insipidus, likely secondary to chronic lithium use. P: 1. Start amiloride 5mg daily to block lithium entry. 2. Discuss lithium cessation or switch with psychiatry. 3. Advise low-sodium diet. 4. Strict fluid balance chart and unrestricted access to free water.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for polyuria and polydipsia with dilute urine: (1) Central Diabetes Insipidus — check response to desmopressin; (2) Nephrogenic Diabetes Insipidus — no response to desmopressin, check for lithium use, hypercalcaemia, or genetic history; (3) Primary Polydipsia — low baseline serum sodium, normalises with water restriction.

📈

Prognosis

SHORT-TERM OUTCOME

With adequate access to free water and appropriate management of the underlying cause, acute hypernatraemia and dehydration can be corrected, and symptoms of polyuria managed. Drug-induced NDI may partially reverse within weeks to months of stopping the offending agent.

LONG-TERM PROGNOSIS

Congenital NDI requires lifelong management; with strict adherence to fluid intake and dietary modifications, patients can have a normal life expectancy, though they remain at risk for chronic kidney disease and urinary tract dilation. Lithium-induced NDI may become irreversible if the drug is continued for years despite polyuria.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

N25.1

LITERATURE CITATIONS & GUIDELINES

[1]Bichet DG. Nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2003;18(10):1979-1981.

[2]Khanna A. Acquired nephrogenic diabetes insipidus. J Intensive Care Med. 2006;21(3):124-128.

[3]Bockenhauer D, Bichet DG. Urinary concentration and dilution. In: Seldin and Giebisch's The Kidney. 5th ed. Academic Press; 2013.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.